Best AI Scribe for Cardiology 2027: LVEF and GDMT Documentation Software Review

The best AI scribe for cardiology in 2027 is one that structures LVEF by date and modality, documents each of the four GDMT pillars with dose or contraindication, links device eligibility to guideline thresholds, and generates audit-defensible MDM without cloned text or unsupported diagnoses.

This playbook is written for clinic medical directors choosing or auditing ambient documentation software for general cardiology, heart failure, and electrophysiology clinics. It sets out the clinical parameters that separate a cardiology-grade scribe from a general transcription tool. It covers the audit exposures that follow from weak notes, and it gives a structured scorecard you can run during a vendor trial. Specialty-specific templates are available through the Specialty Clinical Documentation Library.

Cardiology AI scribes must capture LVEF trajectories, not single values

A single ejection fraction number does not support a heart failure note. Phenotype classification, GDMT eligibility, device candidacy, and quality measure attribution all depend on the trend of LVEF over time, the modality that produced each value, and the clinical context of each measurement. A general-purpose ambient scribe that hears "EF is about 30" and writes "EF 30%" has produced a note that cannot defend an ICD referral, an ARNI prior authorization, or a MIPS numerator.

Current guideline phenotypes require structured thresholds. The 2022 AHA/ACC/HFSA heart failure guideline and the universal definition define four categories. A scribe must assign them from documented values, not from what the clinician said in passing:

• HFrEF (reduced ejection fraction): LVEF of 40% or lower.

• HFmrEF (mildly reduced): LVEF of 41 to 49%.

• HFpEF (preserved ejection fraction): LVEF of 50% or higher, with evidence of structural disease or elevated filling pressures.

• HFimpEF (improved ejection fraction): prior LVEF of 40% or lower, a follow-up value above 40%, and an increase of at least 10 points.

The HFimpEF category exposes weak scribes fastest. A patient whose LVEF rose from 25% to 45% on GDMT is not "HFmrEF." The guideline recommends continuing GDMT in HFimpEF because withdrawal is associated with relapse. A scribe that reclassifies the patient as mildly reduced, based only on today's echo, invites an inappropriate de-escalation decision. It also creates a documentation trail that a payer could later use to question continued sacubitril/valsartan coverage.

Modality and date are not optional metadata. Transthoracic echo, cardiac MRI, nuclear gated SPECT, and ventriculography produce systematically different LVEF values. Device eligibility under CMS coverage policy references a measured LVEF of 35% or lower. Auditors look for the study date, the modality, and whether the measurement followed a sufficient GDMT duration. A cardiology-grade scribe should store each LVEF as a structured triplet (value, modality, date) and render a trajectory line in the assessment. For example: "LVEF 22% (TTE, 03/2025) to 31% (TTE, 09/2025) to 34% (CMR, 02/2026) on four-pillar GDMT since 04/2025."

Diagnosis specificity follows from LVEF structure. When the trajectory and chronicity are explicit, the scribe can support I50.22 (ICD-10-CM) for chronic systolic heart failure instead of defaulting to I50.9. Specificity supports CMS-HCC V28 risk adjustment accuracy and HF quality measure denominators. It also supports clinical clarity when a covering physician reads the note at 2 a.m.

GDMT documentation requires four-pillar status with explicit barriers per drug

"Patient on GDMT" is not documentation. Guideline-directed medical therapy for HFrEF consists of four pillars. Each has its own evidence base, target dose, monitoring requirement, and list of contraindications. An auditor, a quality analyst, or a peer reviewer needs to see the status of each pillar on every heart failure visit:

• Renin-angiotensin system inhibition: ARNI (sacubitril/valsartan) preferred, ACE inhibitor or ARB when ARNI is not feasible.

• Evidence-based beta blocker: carvedilol, metoprolol succinate, or bisoprolol, titrated toward target dose.

• Mineralocorticoid receptor antagonist: spironolactone or eplerenone, with potassium and renal monitoring.

• SGLT2 inhibitor therapy: dapagliflozin or empagliflozin, now also supported in HFmrEF and HFpEF.

Every missing pillar needs a documented reason. The reason must be clinical and specific. "Hypotension" alone is weak. "Symptomatic orthostatic hypotension, seated SBP 88 mmHg, lightheadedness on standing, ARNI dose held at 24/26 mg twice daily" is defensible. For MRA, the common barriers are serum potassium above 5.0 mEq/L or eGFR below 30 mL/min/1.73 m². For ARNI, a history of angioedema is an absolute contraindication. For SGLT2 inhibitors, recurrent genital mycotic infection or type 1 diabetes with ketoacidosis risk are typical. For beta blockers, decompensated volume status or advanced heart block without pacing support are the common holds.

Quality measures read these sentences literally. MIPS Quality Measure #005 (ACE inhibitor, ARB, or ARNI therapy for LVSD) and #008 (beta blocker therapy for LVSD) accept documented medical, patient, or system reasons for non-prescription. A scribe that omits the reason converts a legitimate exclusion into a performance failure. Across a heart failure panel of several hundred patients, that gap can move a practice from a positive to a negative payment adjustment.

Titration intent belongs in the plan. A defensible GDMT plan states current dose, target dose, the next titration step, the monitoring trigger, and the follow-up interval. For example: "Metoprolol succinate 50 mg daily, target 200 mg. Increase to 100 mg if resting HR above 70 and SBP above 100 at 2-week nurse visit. BMP in 7 days after spironolactone start." This language also supports moderate-risk or high-risk MDM under the 2021 E/M framework, because it shows prescription drug management with active monitoring.

Callout: Name the drug, the dose, and the barrier for every pillar.

Eight parameters determine whether a cardiology note survives audit

The table below maps each high-risk clinical parameter to its documentation requirement, the specific audit exposure it creates, and the structured mechanism the Scribing.io Clinical Interface uses to capture it. Use it as a checklist during vendor evaluation.

Device eligibility notes fail without dated LVEF, QRS, and GDMT duration

Primary prevention ICD documentation is among the most audited content in outpatient cardiology. CMS National Coverage Determination 20.4 requires specific elements for patients with ischemic or nonischemic cardiomyopathy. These include LVEF of 35% or lower, NYHA class II or III (or class I with ischemic cardiomyopathy and LVEF of 30% or lower), and optimal medical therapy for an adequate period. Patients must be at least 40 days post myocardial infarction and 90 days post revascularization where applicable. Expected survival beyond one year with good functional status is also required. A formal shared decision-making encounter using an evidence-based decision tool must occur before implantation.

Each of these elements must appear in the referring note, not only in the implanting electrophysiologist's record. Payers increasingly request the referring cardiologist's documentation during prepayment review. A scribe that captures "will refer for ICD" without the supporting data shifts denial risk onto the practice and the hospital.

CRT candidacy depends on conduction detail. Cardiac resynchronization therapy has its strongest guideline recommendation for patients with LVEF of 35% or lower, sinus rhythm, NYHA class II to ambulatory IV on GDMT, and left bundle branch block with QRS duration of 150 ms or more. When LBBB is present, the note should support I44.7 (ICD-10-CM) with the measured QRS duration and the ECG date. Non-LBBB morphology and QRS between 120 and 149 ms carry weaker recommendations. In those cases the scribe should record morphology explicitly, so reviewers can see the clinician weighed the lower evidence tier.

Ambient capture must not invent numbers. The most dangerous failure in cardiology AI documentation is a plausible but fabricated value: a QRS of "150 ms" when the clinician said "wide," or an LVEF of "35%" when the clinician said "mid-thirties." A cardiology-grade system should leave the field empty and prompt the clinician rather than infer a threshold-crossing value. During vendor trials, deliberately dictate vague values and confirm the software flags them instead of resolving them.

Callout: A blank field beats a fabricated threshold value every time.

Modifier 25 and G2211 require separate, explicit documentation logic

Same-day procedures create bundling exposure. Cardiology clinics frequently perform minor procedures alongside office visits: device interrogations with reprogramming, trigger point or joint injections in multispecialty groups, and in some settings elective cardioversion. NCCI policy treats the decision to perform a minor procedure, and the routine pre-procedure evaluation, as included in the procedure payment. Modifier 25 is appropriate only when the E/M service is significant and separately identifiable. Detailed bundling logic is covered in Managing Modifier 25 Clinical Revenue Integrity.

The separating content is usually GDMT management. A patient seen for a device check who also undergoes beta blocker titration, potassium review for MRA continuation, and diuretic adjustment for 2 kg weight gain has received a separately identifiable service. The scribe must place that work in its own E/M section with its own assessment and plan. When the E/M narrative simply restates the reason for the procedure, auditors will recoup the visit.

G2211 rewards longitudinal heart failure care. The visit complexity add-on applies to office and outpatient E/M services when the clinician is the continuing focal point for all needed services or for ongoing care of a single serious or complex condition. Chronic heart failure managed over years by the same cardiologist fits this definition well. The note should state the relationship explicitly. CMS generally does not pay G2211 when the E/M is reported with Modifier 25. The exceptions, added in the CY 2025 Physician Fee Schedule, cover same-day annual wellness visits, vaccine administration, and Medicare Part B preventive services. A scribe should never insert G2211 language automatically. It should prompt the clinician to confirm the relationship and suppress the add-on when Modifier 25 logic is active outside those exceptions.

MDM leveling should reflect cardiology reality. Under the 2021 office E/M framework, prescription drug management supports moderate risk. Drug therapy requiring intensive monitoring for toxicity supports high risk, which can apply to antiarrhythmics such as dofetilide or amiodarone when monitoring labs or ECGs are reviewed for toxicity. Independent interpretation of an echo or ECG counts as a data element only when the clinician is not separately billing that interpretation. A scribe that counts a billed 93000 interpretation toward MDM data creates an overcoding pattern that is easy for payers to detect.

Regulatory guardrails for 2027 shape cardiology AI scribe selection

State AI laws now affect vendor choice. California AB 3030, effective January 2025, requires disclosure when generative AI produces patient clinical communications, unless a licensed provider reviews the content before sending. Cardiology practices that use AI-drafted portal messages about medication changes or echo results must either route them through clinician review or include the required disclaimer. California SB 1120 restricts health plans from letting algorithms alone deny or modify care based on medical necessity. That makes the physician's documented clinical reasoning more important during utilization review, not less.

Note cloning remains the dominant audit signal. CMS and commercial payers use similarity analysis to identify templated or copied documentation across visits. Heart failure notes are especially prone to cloning because the problem list, medication list, and plan change slowly. A scribe should regenerate each interval history from the current encounter transcript. It should carry forward only structured data (prior LVEF values, therapy start dates), and visibly mark carried-forward elements as historical.

Data handling must meet HIPAA requirements and your BAA terms. Confirm that audio is processed under a signed Business Associate Agreement. Confirm retention periods, whether de-identified data trains vendor models, and whether the vendor supports audit logs showing which clinician signed each AI-generated section. Medical directors should treat these as gating criteria, not negotiation points.

Medical directors should test scribes on five scripted cardiology scenarios

Vendor demonstrations rarely reveal failure modes. Run a structured two-week pilot with scripted encounters that stress the parameters in the comparison table. Score each output against a fixed rubric before reviewing marketing claims.

1. The HFimpEF reclassification trap: Present a patient with LVEF improving from 25% to 46% on GDMT. Pass criterion: the note classifies HFimpEF and recommends continuing all four pillars.

2. The partial GDMT visit: Dictate that spironolactone is held for potassium of 5.4 mEq/L and SGLT2 inhibitor is held for recurrent mycotic infection. Pass criterion: both barriers appear with values, and MIPS exclusion language is present.

3. The vague value test: Say "EF in the mid-thirties" and "QRS is wide." Pass criterion: the system prompts for exact values instead of inserting 35% or 150 ms.

4. The ICD readiness visit: Discuss primary prevention ICD with a nonischemic patient on GDMT for 110 days. Pass criterion: LVEF date and modality, GDMT start date, NYHA class, survival expectation, and SDM tool all appear.

5. The same-day procedure visit: Combine a device interrogation with diuretic and beta blocker titration. Pass criterion: separate E/M and procedure sections, with no automatic G2211 insertion.

Score each scenario on three axes: clinical accuracy, audit defensibility, and clinician edit time. A scribe that produces accurate notes but requires six minutes of editing per visit has not solved the problem. Target under 90 seconds of review per established heart failure visit after the first week of use.

Callout: Score accuracy, defensibility, and edit time on every scripted scenario.

A 30-day rollout protects revenue while clinicians adopt ambient documentation

Week one establishes the baseline. Pull 30 recent heart failure notes per participating cardiologist. Record the percentage with dated LVEF, four-pillar GDMT status, documented barriers, and specific I50.2x, I50.3x, or I50.4x coding. This baseline lets you measure improvement and justify the software cost to your board.

Week two configures specialty templates. Load heart failure, atrial fibrillation, post-PCI, and device clinic templates from the 1,000+ Specialty Clinical Macros library. Adjust target doses, local monitoring intervals, and preferred SDM tools to match your clinic's protocols. Assign one physician champion and one coding lead to approve template language.

Week three runs parallel documentation. Clinicians use the AI scribe while coders compare AI-generated notes against the baseline standard. Track fabricated values, missing barriers, and incorrect phenotype assignments. Any fabricated threshold value should trigger an immediate vendor escalation.

Week four measures and decides. Re-audit 30 notes per clinician. A cardiology-grade scribe should raise dated LVEF capture and four-pillar documentation close to 100% for HFrEF visits. It should also reduce I50.9 usage substantially and cut after-hours documentation time. If those outcomes are not visible by day 30, the software is not fit for a cardiology service line.

The best 2027 cardiology AI scribe is defined by structured clinical reasoning

Transcription accuracy is now table stakes. Every major ambient vendor can convert speech to readable prose. The differentiator for cardiology is whether the software understands that an ejection fraction has a date and a modality, that GDMT has four pillars with individual barriers, and that device eligibility rests on thresholds a payer will verify. It must also respect the boundaries of Modifier 25 and G2211, and refuse to invent numbers that cross clinical thresholds.

Medical directors should evaluate vendors against those criteria, using scripted scenarios and pre-defined pass thresholds. Choose the system that makes your clinicians' reasoning visible, auditable, and specific. That choice protects patients from inappropriate therapy changes and protects the practice from recoupment.

Frequently asked questions about cardiology AI scribes for LVEF and GDMT

What LVEF thresholds should a cardiology AI scribe document for heart failure classification?

A cardiology AI scribe should document LVEF with modality and date, then classify HFrEF at 40% or lower, HFmrEF at 41 to 49%, HFpEF at 50% or higher, and HFimpEF when a prior value of 40% or lower improves above 40% with at least a 10-point gain.

Which ICD-10-CM codes matter most for heart failure and conduction documentation?

I50.22 captures chronic systolic heart failure and requires documented chronicity plus reduced ejection fraction. I44.7 captures left bundle branch block, which supports CRT evaluation when QRS duration reaches 150 ms or more. Unspecified I50.9 weakens quality measure attribution, risk adjustment accuracy, and payer review.

When can cardiology practices bill Modifier 25 with an E/M visit?

Modifier 25 applies when the E/M service is significant and separately identifiable beyond the usual pre-procedure and post-procedure work of a same-day minor procedure. The note must show distinct history, assessment, and management decisions, such as GDMT titration, that would justify the visit independently.

Can G2211 be billed for longitudinal heart failure management?

G2211 applies to office and outpatient E/M visits when the clinician serves as the continuing focal point for a serious or complex condition such as chronic heart failure. The note should state the longitudinal relationship. CMS generally denies G2211 when Modifier 25 is appended, with limited preventive service exceptions.

What documentation defends a primary prevention ICD referral during audit?

Auditors expect a dated LVEF of 35% or lower, at least 90 days of documented GDMT (40 days after myocardial infarction), NYHA class, QRS duration, expected survival beyond one year, and a shared decision-making encounter using an evidence-based tool, as required under CMS NCD 20.4.